Dudediligence.

Intellia Therapeutics, Inc

NTLANASDAQ · In Vitro & in Vivo Diagnostic Substances
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$9.1MSep ’24$12.9MDec ’24$16.6MMar ’25$14.2MJun ’25$13.8MSep ’25$23.0MDec ’25$15.0MMar ’26$7.7MJun ’26
Net income, by quarter
−$135.7MSep ’24−$128.9MDec ’24−$114.3MMar ’25−$101.3MJun ’25−$101.3MSep ’25−$95.8MDec ’25−$96.2MMar ’26−$106.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$33.1M$52.1M$36.3M$57.9M$67.7M
Gross profit$33.1Mnone on filenone on filenone on filenone on file
Operating income−$267.9M−$458.2M−$515.3M−$534.3M−$441.0M
Net income−$267.9M−$474.2M−$481.2M−$519.0M−$412.7M
Operating cash flow−$225.0M−$333.3M−$394.1M−$348.9M−$394.7M
Free cash flow−$237.8M−$346.8M−$408.1M−$354.7M−$395.9M
Cash$123.4M$523.5M$226.7M$189.2M$155.5M
Shares outstanding74.5M87.1M93.0M102.0M116.3M